Option chain shows key data for Hertz Global Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Hertz Global Holdings.

Hertz Global Holdings (NASDAQ:HTZWW) Stock, Option Chain

Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through Hertz, Dollar and Thrifty brands. The Company has identified two reportable segments: Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean; International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The Company maintain a substantial network of company-operated rental locations, a majority of which are in Europe, and have franchisees and partners that operate rental locations under brands. Geographical markets includes U.S., Europe, Pacific Asia, Middle East and Africa, Latin America.

Emerging Markets

Small Cap

Markets

BLNK

HTZWW

LCID

RIVN

SIEGY

TSLA

Photo by Bob Osias on Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

The largest journeys can often begin with small steps.

This EV Rental Company Hopes to Build Revenue and Expand Its Segment One Step at a Time

News

Penny Stocks

Sector ETFs

Broad U.S. Equity ETFs

Tech

ETFs

XPEV

DIDI

Cathie Wood’s Ark Investment Management on Wednesday bought more shares in the U.S listed Chinese electric vehicle maker Xpeng Inc (NYSE: XPEV) on the dip and sold more shares in Tesla Inc (NASDAQ: 

Cathie Wood Sheds Another $30M In Tesla But Continues Buying Spree In This Chinese EV Maker

Retail Sales

Exclusives

UBER

Hertz Global Holdings (NASDAQ: HTZWW) told Benzinga on Tuesday it is planning a wider national rollout of Tesla Inc (NASDAQ: TSLA) electric vehicles in more markets next year for its fleet an

Hertz Suggests &#39;First Wave Of National Rollout&#39; Of Tesla EVs On Track, Prepares To Expand To &#39;New Markets&#39;

Hertz Global Holdings Inc

WIIM

Teleflex shares are trading lower after the company issued FY25 EPS guidance below estimates.

WRBY

Warby Parker shares are trading higher after the company reported Q4 sales above estimates.

Barclays analyst Jeffrey Bernstein maintains Bloomin Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) with a Equal-Weight and lowers the price target from $13 to $11.

Price Target

Analyst Ratings

BLMN

Barclays Maintains Equal-Weight on Bloomin Brands, Lowers Price Target to $11

2025 Full-Year Financial Guidance1
The Company's full-year guidance for 2025 can be found in the table below.
Updates to Subsea guidance, previously issued on October 24, 2024, are as follows:
<ul>
<li>Subsea revenue in a range of $8.4 - 8.8 billion, which increased from the previous guidance range of $8.3 - 8.7 billion.</li>
<li>Subsea adjusted EBITDA margin in a range of 19 - 20%, which increased from the previous guidance range of 18.5 - 20%.</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5" rowspan="1">2025 Guidance (As of February 27, 2025)</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Subsea</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Surface Technologies</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Revenue in a range of $8.4 - 8.8 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Revenue in a range of $1.2 - 1.35 billion</td>
</tr>
<tr>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Adjusted EBITDA margin in a range of 19 - 20%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Adjusted EBITDA margin in a range of 15 - 16%</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">TechnipFMC</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Corporate expense, net $115 - 125 million</td>
</tr>
<tr>
<td colspan="5" rowspan="1">(excludes charges and credits)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Net interest expense $45 - 55 million</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Effective tax rate 28 - 32%</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Capital expenditures approximately $340 million</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Free cash flow2 $850 million - 1 billion</td>
</tr>
</tbody>
</table>
</figure>

Earnings

Guidance

TechnipFMC 2025 Outlook: Raised Subsea Revenue Range To $8.4B - $8.8B From $8.3B - 8.7B And Adj. EBITDA Margin Range To 19% - 20% From 18.5% - 20%.

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell and maintains $75 price target.

Reiteration

SRPT

HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target

VTRS

Viatris shares are trading lower after the company reported Q4 EPS and sales below estimates.

2025 Financial Guidance
The Company is providing the following financial guidance metrics for fiscal year 2025.
The Company's financial guidance metrics for fiscal year 2025 include the anticipated negative impact from the Indore facility of ~$500 million to total revenues and ~$385 million to adjusted EBITDA. The Company is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or U.S. GAAP diluted earnings (loss)&nbsp;per share (EPS) or a quantitative reconciliation of its 2025 adjusted EBITDA or adjusted EPS guidance to the most directly comparable U.S. GAAP measures, U.S. GAAP net earnings (loss) or U.S. GAAP diluted EPS, respectively, because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset impairments, litigation settlements, and other contingencies, such as changes to contingent consideration, acquired IPR&amp;D and certain other gains or losses, including for the fair value accounting for non-marketable equity investments, as well as related income tax accounting, because certain of these items have not occurred, are out of the Company's control and/or cannot be reasonably predicted without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period. U.S. GAAP net cash provided by operating activities for 2025 is estimated to be between $2.2 billion and $2.5 billion, with a midpoint of approximately $2.35 billion.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(In millions, except Adjusted EPS)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Estimated Guidance&nbsp; Range</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Midpoint</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$13,500 - $14,000</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$13,750</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3,900 - $4,200</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$4,050</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS (1)(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2.12 - $2.26</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2.19</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow (1)(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1,800 - $2,200</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2,000</td>
</tr>
</tbody>
</table>
</figure>

Viatris FY2025 Outlook: Adj EPS $2.12-$2.26 vs $2.60 Estimate; Sees Sales $13.500B-$14.000B vs $14.31B Estimate

Offerings

SLB Subsidiary Commences Offer To Exchange Certain Outstanding Existing Series Of Notes For Up To $2B Of New Series Of Notes

Viatris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) reported quarterly earnings of $0.54 per share which missed the analyst consensus estimate of $0.57 by 5.26 percent. This is a 12.9 percent decrease over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $3.52 billion which missed the analyst consensus estimate of $3.61 billion by 2.75 percent. This is a 8.13 percent decrease over sales of $3.83 billion the same period last year.

Earnings Misses

Viatris Q4 2024 Adj EPS $0.54 Misses $0.57 Estimate, Sales $3.52B Miss $3.61B Estimate

HC Wainwright &amp; Co. analyst Ed Arce maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $400 to $405.

MDGL

HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $405

Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. The company reported quarterly sales of $190.64 million which beat the analyst consensus estimate of $187.64 million by 1.60 percent. This is a 17.79 percent increase over sales of $161.85 million the same period last year.

Earnings Beats

Warby Parker Q4 2024 GAAP EPS $(0.06) Misses $(0.05) Estimate

The planned spin-off will result in two separate, publicly traded companies:
<ul>
<li>Costamare Inc. will remain a global container shipping provider, retaining the owned container vessels and Neptune Maritime Leasing Limited businesses.</li>
<li>Costamare Bulkers Holdings Limited will be an international owner and operator of dry bulk vessels and will hold the owned dry bulk vessels and the CBI operating platform.</li>
</ul>

General

CMRE

Costamare Announced Its Intent To Spin-off The Company's Dry Bulk Business Into A Standalone Company, Costamare Bulkers Holdings Limited

NCLH

Norwegian Cruise Line Says Q1 2025 Net Yield Set To Increase ~$0.5% On Constant Currency Basis YoY

Warby Parker Expects FY25 Net Revenue Of $878M - $893M (Est $872.097M), Representing Approximately 14% - 16% Growth YoY

Norwegian Cruise Line Sees FY25 Adj. Net Income ~$1.065B; Sees Adj. EPS ~$2.05 Vs $2.08 Estimate

Full Year 2025 Guidance
For the full year of 2025, excluding any contribution from the recently announced Australian asset acquisition, Civeo expects revenues of $630.0 million to $660.0 million, Adjusted EBITDA of $80.0 million to $90.0 million and capital expenditures of $25.0 million to $30.0 million. This guidance takes into account the recent reduction in currency exchange rates experienced since late 2024.
The Company expects the recently announced Australian asset acquisition to be completed by the end of the second quarter of 2025, subject to regulatory approvals and customary conditions, and we will provide updated 2025 guidance upon completion.

CVEO

Civeo 2025 Outlook: Expects Revenue Of $630M-$660M Vs. $719.51M Est.; Sees Adjusted EBITDA Of $80M-$90M

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Buy and maintains $40 price target.

KURA

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target

Life Time Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) raises FY2025 sales outlook from $2.91 billion-$2.97 billion to $2.92 billion-$2.98 billion vs $2.93 billion estimate.

Life Time Group Hldgs Raises FY2025 Sales Guidance from $2.91B-$2.97B to $2.92B-$2.98B vs $2.93B Est

Life Time Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.15 by 80 percent. This is a 42.11 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $663.30 million which beat the analyst consensus estimate of $657.76 million by 0.84 percent. This is a 18.69 percent increase over sales of $558.83 million the same period last year.

Life Time Group Hldgs Q4 Adj $0.27 Beats $0.15 Estimate, Sales $663.30M Beat $657.76M Estimate

2025 Outlook
For the full-year 2025, the Company is providing the following outlook:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Total Revenue</td>
<td colspan="1" rowspan="1">$2,575M – $2,650M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Software and Services Revenue</td>
<td colspan="1" rowspan="1">$1,995M – $2,020M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Hardware Revenue</td>
<td colspan="1" rowspan="1">$580M – $630M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$420M – $445M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (%)</td>
<td colspan="1" rowspan="1">16.3% – 16.8%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Diluted EPS</td>
<td colspan="1" rowspan="1">$0.75 - $0.80</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Free Cash Flow - Unrestricted1</td>
<td colspan="1" rowspan="1">$170M - $190M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Conversion (as % of Adjusted EBITDA)</td>
<td colspan="1" rowspan="1">40% - 43%</td>
</tr>
</tbody>
</table>
</figure>

Comments

Hertz Global Holdings

Hertz Global Holdings (HTZWW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga